Phase II: Non Small Cell Lung Cancer (Erbitux)


Study: Efficacy/Safety of Imprime PGG® Injection with Cetuximab and Paclitaxel/Carboplatin Therapy in Patients with Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)


ClinicalTrials.gov Id: NCT00874848


Biothera has initiated an open label, randomized Phase II clinical trial analyzing the combination of Imprime PGG, cetuximab (Erbitux®) and two chemotherapeutic agents in up to 90 patients.


Status: Closed/Fully Enrolled.




Site design by Checkerboard